Psychedelic integration, explained

What integration means

There is no single agreed definition. A 2022 review compared 24 distinct definitions and merged them into one. In that definition, a person returns to the experience, works through what came up, and gradually carries its lessons into thought, relationships and daily life. None of the definitions treats difficult content as a sign of illness.

The work starts before the experience. Preparation covers intentions and expectations, a plan for safety and support, and time set aside for afterwards. The same review suggests getting to know a professional in advance, so that someone familiar is available if things become hard. In harm-reduction work outside legal settings, the practitioner helps a person weigh risks, benefits and alternatives without arguing for or against use.

Preparation is also the moment for screening. The Johns Hopkins safety guidelines for research exclude people with a current or past psychotic or bipolar disorder, and people with a first- or second-degree relative who has one. Some medicines interact. In 62 online reports of classic psychedelics taken with lithium, 47% described seizures. Ayahuasca with certain antidepressants can cause serotonin syndrome, which can be life-threatening. Medication questions belong with a prescriber, and a prescribed drug should only be stopped under medical supervision.

After the experience, integration means going back over what happened, staying with the harder parts and testing insights in daily life. Several models treat big outward changes, such as leaving a job, as a later step.

The forms integration takes

Integration can be self-guided or supported.

One-to-one therapy is given by licensed or registered clinicians such as psychologists, psychotherapists and psychiatrists, who may adapt a method they already use, such as acceptance and commitment therapy or psychodynamic therapy. One-to-one coaching is aimed at practical problems and building skills, not at treating a condition.

Integration circles and peer groups give people a place to describe an experience and hear others describe theirs. Sharing circles appear in several integration models, which favour supportive company over isolation but advise against confiding in people who dismiss the experience. A community of people who use psychedelics can support someone in some ways and hold them back in others.

Somatic and creative practices work through the body and through making things. The models list drawing, painting and mandalas, journaling and letter writing, music and singing, dance, yoga, tai chi and qigong, walks in nature, and meditation with attention on the breath. Body-based work aims to help people notice and settle emotion as it shows up physically.

What research and clinical frameworks say

Clinical trials surround each drug session with psychological support: usually a few preparation sessions, support during dosing and, after each dose, a few integration sessions. The Johns Hopkins research guidelines describe at least eight hours of preparatory meetings over at least four sessions, usually across a month, so that trust exists before the first dose.

Several frameworks give integration a structure. The ACE model (Accept, Connect, Embody), first published in 2020, took shape during an Imperial College London trial comparing psilocybin with the antidepressant escitalopram. Drawing partly on acceptance and commitment therapy, it centres on trust, accepting hard emotions rather than avoiding them, connecting with values and other people, and mindful attention to the body. Psychedelic Harm Reduction and Integration (PHRI), from 2021, guides therapists whose clients use psychedelics outside legal treatment; the therapist does not encourage use, provide the drug or take part in the experience. The 2022 review found ten integration models, all published since 2017, and combined them into one with six areas: mind, body, spirit, relationships, nature and lifestyle.

The weak point is evidence. Integration is built into trial protocols, but its separate effect has not been measured. The US Food and Drug Administration’s final guidance on psychedelic trials, issued in July 2026, states that it is not yet known how much the psychotherapy component adds to any benefit. The PHRI authors acknowledge a lack of empirical evidence for their own approach.

The legal position

Integration support involves no substance: the practitioner listens, asks questions and teaches practices, and supplies nothing, so the work can generally be offered lawfully where the substances themselves are prohibited. A 2021 legal and ethical analysis notes that in most countries clinicians cannot prescribe psychedelics or act as guides. With care, though, they can offer therapy before and after experiences that clients arrange themselves. The paper’s legal detail concerns the United States: a California case that let doctors discuss cannabis with patients before legalisation suggests therapists may also discuss psychedelics as protected speech. That protection ends if a practitioner helps a client obtain a drug, refers them to a seller or underground guide, or lets them attend a session under the influence. Such steps could bring charges such as conspiracy or aiding and abetting. The authors see licensing boards as perhaps the largest risk for clinicians, and preparation as riskier than integration, because a client could later say the therapist’s involvement made them go ahead.

Where psilocybin services are licensed, preparation is regulated: in Oregon, as of October 2026, a preparation session with a licensed facilitator must come before any psilocybin session at a licensed service centre. Laws differ between countries, and this guide is not legal advice. A legitimate integration practitioner does not sell, source or point to sources of substances, and does not run or attend sessions where illegal drugs are taken. They do not push anyone towards use, though they will name the risks of a plan.

Therapist, coach or peer group

The deciding question is whether something needs assessment or treatment. Therapy is aimed at diagnosable mental health conditions, while coaching deals with practical problems and skills, and coaches are generally not required to hold clinical degrees or training. A licensed clinician is the safer choice for anyone with a current or past mental health diagnosis, anyone taking psychiatric medication, and anyone who finds old trauma resurfacing. The same applies to sleeplessness, disorientation, anxiety or low mood that continue after the drug’s effects have ended, which the PHRI authors treat as a sign that further therapeutic support is needed. Telling manageable distress apart from a more serious reaction, such as a psychotic episode, is clinical work.

A coach, a peer group or self-guided practice can suit someone who is broadly well and wants help to reflect, keep up new habits or find company. A good coach knows where the role ends and helps a client move into mental health care when that is needed. The options can run side by side: a clinician for symptoms, a group for connection.

Difficult experiences and when to get help

Distress after a hard experience usually passes without lasting illness. In an online survey of 1,993 people about their most difficult experience with psilocybin mushrooms, 39% ranked it among the five most challenging events of their lives, yet 84% said they had benefited. A minority needed more: 2.7% received medical help, and of those whose experience was over a year earlier, 7.6% sought treatment for lasting psychological symptoms. Three cases appeared linked to the onset of lasting psychotic symptoms and three to suicide attempts. People treated for psychological symptoms beforehand were more than twice as likely to seek treatment afterwards. A 2023 survey of 608 people whose difficulties lasted more than a day found the most common to be anxiety and fear, existential struggle, social disconnection, and feeling detached from oneself or reality. For about a third, problems lasted over a year. Both surveys recruited people who had had difficulties, so neither shows how often problems occur.

Some signs call for prompt help:

• Thoughts of suicide or self-harm, or a person who cannot be kept safe, warrant a call to the local emergency number at once (in the US, 911, or 988 for suicidal thoughts).
• A seizure, chest pain or collapse during or after use is a medical emergency.
• Hearing or seeing things others do not, firm beliefs others do not share, or racing, jumbled speech after the drug has worn off needs a doctor the same day.
• Visual effects that keep returning after use and cause distress (hallucinogen persisting perception disorder) need a medical assessment.
• Anxiety, panic, low mood, poor sleep or a sense of unreality that does not settle is a reason to see a licensed clinician.

Choosing an integration practitioner

There is no agreed training standard yet, so questions reveal more than titles. A careful practitioner can name any licence or registration, which can be checked on a public register, and say who handles complaints. They can describe their training, who supervises them, and which doctors and therapists they refer to when a client needs more. They explain in writing what the service includes and excludes, state that they do not help clients obtain substances, and describe the evidence without presenting psychedelics as a cure.

Warning signs include an offer to supply or source a substance or to guide a session, a promise of healing, pressure to stop medication, and any sexual or romantic contact. Sexual abuse by guides and shamans has been reported, and sexual touch is no part of traditional ayahuasca ceremonies. Anyone booking a retreat can ask what support continues at home; the 2023 survey’s authors recommend that providers give written guidance on managing anxiety afterwards. The relationship matters too. In an analysis of 30 people given psilocybin in a depression trial, a stronger alliance with their guides predicted lower depression scores at six weeks, though the sample was small.